Skip to main content
Figure 5 | BMC Cancer

Figure 5

From: Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+

Figure 5

The apoptosis-inhibiting action of p35 does not slow viral spread. qPCR assay measuring helper effect of the replication-competent adenovirus ONYX-017 in facilitating spread of either Adeno-2B6 or Adeno-2B6/p35. Viral particle release and spread is similar between Adeno-2B6 (A) and Adeno-2B6/p35 (B) from infected U251 (left) and A549 cells (right) from day 4 through day 5 post-infection, indicating that the anti-caspase activity of p35 does not interfere with ONYX-017-assisted adenovirus release. The same qPCR primer set for CYP2B6 cDNA was used to determine viral particle release in both panels. qPCR primers for p35 were used to confirm the accuracy of the measured viral particle release in the case of Adeno-2B6/p35 (data not shown). Data shown are mean ± SD, n = 3.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us